Interim data on Spineart’s Baguera-C cervical disc shows the device meets the threshold for a non-inferiority claim compared to a study control, the medtech company said March 11.
Spineart plans to submit premarket approval for the disc in August, according to a news release. The disc’s nucleus can move in all six degrees of freedom with independent angular rotations and independent translational motions.
The investigational device exemption trial is assessing the Baguera-C disc for single-level disc replacement compared to the Mobi-C disc for symptomatic cervical disease. It spans 25 U.S. sites and includes 285 patients.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
